Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

OFIX US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings
Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

OFIX US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Orthofix Medical Inc.(OFIX US)

$6.53-0.142.10%(Market Open · 19:03:04 UTC)
ProfileFinancialsChartingShort InterestEmployees

Overview

Profile

Financials & Metrics

FinancialsChartingShort InterestEmployees

Orthofix Medical Inc.(OFIX US)

$6.53-0.142.10%(Market Open · 19:03:04 UTC)
ProfileFinancialsChartingShort InterestEmployees

Overview

Profile

Financials & Metrics

FinancialsChartingShort InterestEmployees
Ask AI
Ask AI

Orthofix Medical Inc. — Company Profile

Orthofix Medical Inc., founded in 1980 and headquartered in Lewisville, Texas, operates as a global medical technology company focusing on devices and biologics. Its reach extends across the United States, several European nations including Italy, Germany, France, and the United Kingdom, as well as Brazil and other international markets. The company's operations are divided into two main segments: Global Spine and Global Orthopedics. Within the Global Spine division, Orthofix is responsible for the development, production, and distribution of bone growth stimulators. These devices are designed to facilitate bone fusion and serve as a therapeutic intervention for fractures located outside the spine and in the limbs. This segment also creates and commercializes a range of motion preservation and fixation implant products utilized in spinal surgical procedures. Furthermore, it supplies physicians with various tissue forms and synthetic-based regenerative biologic solutions to address a wide spectrum of spinal and orthopedic conditions. The Global Orthopedics segment concentrates on the design, development, and commercialization of specialized orthopedic products. These offerings are essential for procedures involving fracture repair, the correction of deformities, and bone reconstruction. Orthofix distributes its products to a diverse clientele, including physicians, hospitals, outpatient surgery centers, and integrated health delivery systems. This is achieved through a comprehensive sales network that includes its own sales force, independent distributors, and both employed and external sales representatives. The company, previously known as Orthofix International N.V., officially changed its name to Orthofix Medical Inc. in July 2018.

Sector
Industrials
Industry
Commercial Services & Supplies
Exchange
UQ
CEO
Massimo Calafiore
Headquarters
Lewisville, TX, US
IPO Date
Apr 24, 1992
Employees
1,605
Website
www.orthofix.com

Key Metrics

Price
$9.09
Market Cap
$367.43M
Revenue (TTM)
$196.71M
Net Income (TTM)
$-20908000.00
EPS (TTM)
-0.52
P/E (TTM)
-6.12
P/B (TTM)
0.84
Dividend Yield
0.00%
ROE (TTM)
-4.80%

Orthofix Medical Inc. — Company Profile

Orthofix Medical Inc., founded in 1980 and headquartered in Lewisville, Texas, operates as a global medical technology company focusing on devices and biologics. Its reach extends across the United States, several European nations including Italy, Germany, France, and the United Kingdom, as well as Brazil and other international markets. The company's operations are divided into two main segments: Global Spine and Global Orthopedics. Within the Global Spine division, Orthofix is responsible for the development, production, and distribution of bone growth stimulators. These devices are designed to facilitate bone fusion and serve as a therapeutic intervention for fractures located outside the spine and in the limbs. This segment also creates and commercializes a range of motion preservation and fixation implant products utilized in spinal surgical procedures. Furthermore, it supplies physicians with various tissue forms and synthetic-based regenerative biologic solutions to address a wide spectrum of spinal and orthopedic conditions. The Global Orthopedics segment concentrates on the design, development, and commercialization of specialized orthopedic products. These offerings are essential for procedures involving fracture repair, the correction of deformities, and bone reconstruction. Orthofix distributes its products to a diverse clientele, including physicians, hospitals, outpatient surgery centers, and integrated health delivery systems. This is achieved through a comprehensive sales network that includes its own sales force, independent distributors, and both employed and external sales representatives. The company, previously known as Orthofix International N.V., officially changed its name to Orthofix Medical Inc. in July 2018.

Sector
Industrials
Industry
Commercial Services & Supplies
Exchange
UQ
CEO
Massimo Calafiore
Headquarters
Lewisville, TX, US
IPO Date
Apr 24, 1992
Employees
1,605
Website
www.orthofix.com

Key Metrics

Price
$9.09
Market Cap
$367.43M
Revenue (TTM)
$196.71M
Net Income (TTM)
$-20908000.00
EPS (TTM)
-0.52
P/E (TTM)
-6.12
P/B (TTM)
0.84
Dividend Yield
0.00%
ROE (TTM)
-4.80%
ROA (TTM)
-2.36%
Operating Margin
-6.96%
Beta
0.49

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

Orthofix Medical Inc., founded in 1980 and headquartered in Lewisville, Texas, operates as a global medical technology company focusing on devices and biologics. Its reach extends across the United States, several European nations including Italy, Germany, France, and the United Kingdom, as well as Brazil and other international markets. The company's operations are divided into two main segments: Global Spine and Global Orthopedics. Within the Global Spine division, Orthofix is responsible for the development, production, and distribution of bone growth stimulators. These devices are designed to facilitate bone fusion and serve as a therapeutic intervention for fractures located outside the spine and in the limbs. This segment also creates and commercializes a range of motion preservation and fixation implant products utilized in spinal surgical procedures. Furthermore, it supplies physicians with various tissue forms and synthetic-based regenerative biologic solutions to address a wide spectrum of spinal and orthopedic conditions. The Global Orthopedics segment concentrates on the design, development, and commercialization of specialized orthopedic products. These offerings are essential for procedures involving fracture repair, the correction of deformities, and bone reconstruction. Orthofix distributes its products to a diverse clientele, including physicians, hospitals, outpatient surgery centers, and integrated health delivery systems. This is achieved through a comprehensive sales network that includes its own sales force, independent distributors, and both employed and external sales representatives. The company, previously known as Orthofix International N.V., officially changed its name to Orthofix Medical Inc. in July 2018.

Website
www.orthofix.com
Location
Lewisville, TX, US
Phone214 937 2000
Employees1,605
CEOMassimo Calafiore
Sector
Industrials
Industry
Commercial Services & Supplies
IPO DateApr 24, 1992

Latest Documents

News

  • Orthofix (OFIX) Upgraded to Buy: What Does It Mean for the Stock?01:01PM
  • Orthofix Medical Q3 Earnings Call Highlights9 Nov
  • Orthofix Medical Inc. (OFIX) Q3 2026 Earnings Call Transcript9 Nov
  • Orthofix (OFIX) Surpasses Q3 Earnings Estimates9 Nov
  • Orthofix Reports Third Quarter 2026 Results and Revises Full-Year 2026 Guidance9 Nov
  • Orthofix (OFIX) Surges 11.0%: Is This an Indication of Further Gains?5 Nov
  • Orthofix to Report Third Quarter 2026 Financial Results23 Oct
  • SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of Orthofix Medical Inc. (NASDAQ: OFIX)21 Oct
  • Did Orthofix Medical Inc. Insiders Breach their Fiduciary Duties to Shareholders?13 Oct
  • SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of Orthofix Medical Inc. (NASDAQ: OFIX)8 Oct

Key Stats

Trading

Px/Chg 1D$9.09 / -1.30%
Avg Volume360.13K
Beta0.49
Mkt Cap367.43M
FD Mkt Cap383.40M

Float

Shrs Out/Float40.42M / 39.97M
Short Float0.06%
Days to Cover5.46
Stock Repurchased$0.00

Current Valuation

EV481.54M
EV/EBITDA5.10
EV/Sales0.58
P/B0.84
P/S0.45
FCF Yield-7.69%
ROE-4.80%
ROA-2.36%
Current Ratio2.87

Estimates

P/E-6.12
Est P/E0.00
Est EPS-0.68
Est PEG0.00

Valuation

Metric5Yr AvgMay '23May '24May '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings-52.02-18.94-3.27-4.10-216.20-17.57
Price / Sales1.230.810.660.652.181.87
Price / Book Value0.971.110.831.031.070.84
Price / Free Cash Flow-11.58-10.78-4.59-56.8327.27-13.00
ENTERPRISE VALUE METRICS
Enterprise Value529.0344.9578.3612.7627.6481.5
Enterprise Value / Sales1.520.750.770.772.852.45
Enterprise Value / EBITDA-56.6922.03-7.28-17.926.86-287.14
Enterprise Value / EBIT45.47-21.01-4.13-6.50290.71-31.74

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue15.4%464.5460.7746.6799.5822.3
Gross Income12.1%349.6337.2486.3545.9551.7
EBITDA—21.415.7-79.5-34.2-22.4
EBIT58.4%-11.7-16.4-140.0-94.2-73.3
Net Income24.5%-38.4-19.7-151.4-126.0-92.2
EPS (Diluted)4%-1.95-0.98-4.12-3.30-2.28
BALANCE SHEET
Cash & ST Inv-1.7%87.850.733.183.282.0
Total Assets15.6%476.6458.6925.3893.3850.6
Total Liabilities30.1%139.7121.8326.6390.2400.6
Total Shareholder Equity7.5%336.9336.9598.7503.1450.0
CASH FLOW
Net Operating Cash Flow15.9%18.5-11.5-45.825.833.3
Cap Ex15.3%-19.6-23.2-62.1-34.9-34.6
Free Cash Flow3.4%-1.1-34.7-107.8-9.1-1.3

Enterprise Value Bridge

Millions USD18 Nov '26
Price (As of 18 Nov '26)6.58
Basic Shares40.42
Market Cap265.8
Diluted Shares40.91
Fully Diluted Shares Outstanding40.91
Fully Diluted Market Cap269.0
+Consolidated Debt234.6
−In-the-Money Convertible Debt—
+Capital Leases13.0
+Operating Leases—
−Cash & Equivalents-103.8
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value396.6

Segment data

Revenue

by Products and services

  • Global Spine100%

Revenue

by Geography

  • Other Countries61%
  • Italy18%
  • France10%
  • Germany7%
  • Brazil4%

Related companies

Apple Inc.

AAPL US

Kla Corp

KLAC US

Medtronic Public Limited Company

MDT US

Stryker Corp

SYK US

3M Company

MMM US

Northrop Grumman Corp /DE/

NOC US

Coherent Corp.

COHR US

Boston Scientific Corp

BSX US

Lenovo Group Ltd

LNVGY US

Garmin Ltd

GRMN US

HOYA Corporation

HOCPY US

Becton Dickinson & Co

0R19 LN

ROA (TTM)
-2.36%
Operating Margin
-6.96%
Beta
0.49

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

Orthofix Medical Inc., founded in 1980 and headquartered in Lewisville, Texas, operates as a global medical technology company focusing on devices and biologics. Its reach extends across the United States, several European nations including Italy, Germany, France, and the United Kingdom, as well as Brazil and other international markets. The company's operations are divided into two main segments: Global Spine and Global Orthopedics. Within the Global Spine division, Orthofix is responsible for the development, production, and distribution of bone growth stimulators. These devices are designed to facilitate bone fusion and serve as a therapeutic intervention for fractures located outside the spine and in the limbs. This segment also creates and commercializes a range of motion preservation and fixation implant products utilized in spinal surgical procedures. Furthermore, it supplies physicians with various tissue forms and synthetic-based regenerative biologic solutions to address a wide spectrum of spinal and orthopedic conditions. The Global Orthopedics segment concentrates on the design, development, and commercialization of specialized orthopedic products. These offerings are essential for procedures involving fracture repair, the correction of deformities, and bone reconstruction. Orthofix distributes its products to a diverse clientele, including physicians, hospitals, outpatient surgery centers, and integrated health delivery systems. This is achieved through a comprehensive sales network that includes its own sales force, independent distributors, and both employed and external sales representatives. The company, previously known as Orthofix International N.V., officially changed its name to Orthofix Medical Inc. in July 2018.

Website
www.orthofix.com
Location
Lewisville, TX, US
Phone214 937 2000
Employees1,605
CEOMassimo Calafiore
Sector
Industrials
Industry
Commercial Services & Supplies
IPO DateApr 24, 1992

Latest Documents

News

  • Orthofix (OFIX) Upgraded to Buy: What Does It Mean for the Stock?01:01PM
  • Orthofix Medical Q3 Earnings Call Highlights9 Nov
  • Orthofix Medical Inc. (OFIX) Q3 2026 Earnings Call Transcript9 Nov
  • Orthofix (OFIX) Surpasses Q3 Earnings Estimates9 Nov
  • Orthofix Reports Third Quarter 2026 Results and Revises Full-Year 2026 Guidance9 Nov
  • Orthofix (OFIX) Surges 11.0%: Is This an Indication of Further Gains?5 Nov
  • Orthofix to Report Third Quarter 2026 Financial Results23 Oct
  • SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of Orthofix Medical Inc. (NASDAQ: OFIX)21 Oct
  • Did Orthofix Medical Inc. Insiders Breach their Fiduciary Duties to Shareholders?13 Oct
  • SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of Orthofix Medical Inc. (NASDAQ: OFIX)8 Oct

Key Stats

Trading

Px/Chg 1D$9.09 / -1.30%
Avg Volume360.13K
Beta0.49
Mkt Cap367.43M
FD Mkt Cap383.40M

Float

Shrs Out/Float40.42M / 39.97M
Short Float0.06%
Days to Cover5.46
Stock Repurchased$0.00

Current Valuation

EV481.54M
EV/EBITDA5.10
EV/Sales0.58
P/B0.84
P/S0.45
FCF Yield-7.69%
ROE-4.80%
ROA-2.36%
Current Ratio2.87

Estimates

P/E-6.12
Est P/E0.00
Est EPS-0.68
Est PEG0.00

Valuation

Metric5Yr AvgMay '23May '24May '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings-52.02-18.94-3.27-4.10-216.20-17.57
Price / Sales1.230.810.660.652.181.87
Price / Book Value0.971.110.831.031.070.84
Price / Free Cash Flow-11.58-10.78-4.59-56.8327.27-13.00
ENTERPRISE VALUE METRICS
Enterprise Value529.0344.9578.3612.7627.6481.5
Enterprise Value / Sales1.520.750.770.772.852.45
Enterprise Value / EBITDA-56.6922.03-7.28-17.926.86-287.14
Enterprise Value / EBIT45.47-21.01-4.13-6.50290.71-31.74

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue15.4%464.5460.7746.6799.5822.3
Gross Income12.1%349.6337.2486.3545.9551.7
EBITDA—21.415.7-79.5-34.2-22.4
EBIT58.4%-11.7-16.4-140.0-94.2-73.3
Net Income24.5%-38.4-19.7-151.4-126.0-92.2
EPS (Diluted)4%-1.95-0.98-4.12-3.30-2.28
BALANCE SHEET
Cash & ST Inv-1.7%87.850.733.183.282.0
Total Assets15.6%476.6458.6925.3893.3850.6
Total Liabilities30.1%139.7121.8326.6390.2400.6
Total Shareholder Equity7.5%336.9336.9598.7503.1450.0
CASH FLOW
Net Operating Cash Flow15.9%18.5-11.5-45.825.833.3
Cap Ex15.3%-19.6-23.2-62.1-34.9-34.6
Free Cash Flow3.4%-1.1-34.7-107.8-9.1-1.3

Enterprise Value Bridge

Millions USD18 Nov '26
Price (As of 18 Nov '26)6.58
Basic Shares40.42
Market Cap265.8
Diluted Shares40.91
Fully Diluted Shares Outstanding40.91
Fully Diluted Market Cap269.0
+Consolidated Debt234.6
−In-the-Money Convertible Debt—
+Capital Leases13.0
+Operating Leases—
−Cash & Equivalents-103.8
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value396.6

Segment data

Revenue

by Products and services

  • Global Spine100%

Revenue

by Geography

  • Other Countries61%
  • Italy18%
  • France10%
  • Germany7%
  • Brazil4%

Related companies

Apple Inc.

AAPL US

Kla Corp

KLAC US

Medtronic Public Limited Company

MDT US

Stryker Corp

SYK US

3M Company

MMM US

Northrop Grumman Corp /DE/

NOC US

Coherent Corp.

COHR US

Boston Scientific Corp

BSX US

Lenovo Group Ltd

LNVGY US

Garmin Ltd

GRMN US

HOYA Corporation

HOCPY US

Becton Dickinson & Co

0R19 LN